SOVEREIGNTY | EQUITY | BENEFIT
The ACT Node will establish the role of reference genomes and panels of variation.
The NSW Node will focus on the leading contributors to Indigenous health inequality – Type 2 Diabetes (T2D), Cardiovascular Disease (CVD), and Cancer.
The QLD Node will develop a nationally-endorsed roadmap for pharmacogenomic benefit among Indigenous populations.
The SA Node is responsible for ensuring that the national consortium have a clear vision of success, and are supported to achieve this.
The Immunogenomics Flagship will develop a framework for sustainable access to genomic services and benefits from research for Indigenous Australians.
This Flagship will implement and evaluate initiatives to improve identification of Indigenous patients with rare diseases and provide them and their families with culturally-appropriate and equitable genomic and related healthcare services.
We welcome you to join our network! We'll send you quarterly newsletters to let you know about our activities and how we are progressing!